TrialDiabetes care2026

Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.

Henrik Maagensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.